MannKind to Present at the Jefferies Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present and share updates during the Jefferies ...
MannKind to Present at the Jefferies Global Healthcare Conference - MannKind ( NASDAQ:MNKD )
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( NASDAQ:MNKD ) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present and share updates during the Jefferies ...
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease - MannKind ( NASDAQ:MNKD )
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial ( NTM ) lung disease, following a futility determination based on medical monitoring data
Ligand ( LGND ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Nov. 6, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
MannKind ( MNKD ) Tops Q3 Earnings and Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of +200.00% and +1.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update - MannKind ( NASDAQ:MNKD )
sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026 FUROSCIX ReadyFlow™ Autoinjector sNDA submitted to the FDA MNKD-101 NTM global Phase 3 trial ( ICoN-1 ) achieved interim enrollment target ahead of schedule
Protagonist Therapeutics ( PTGX ) Expected to Beat Earnings Estimates: Should You Buy?
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application ( sBLA ) for Inhaled Insulin ( Afrezza ) in Children and Adolescents Aged 4-17 Years Living with Diabetes - MannKind ( NASDAQ:MNKD )
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application ( sBLA ) for Inhaled Insulin ( Afrezza ) in Children and Adolescents Aged 4-17 Years Living with Diabetes
MannKind Announces U.S. FDA Accepts for Review its sBLA for Inhaled Insulin in Children and Adolescents Aged ...
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care - MannKind ( NASDAQ:MNKD )
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( NASDAQ:MNKD ) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) successfully completed the previously announced acquisition of scPharmaceuticals Inc.
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer - MannKind ( NASDAQ:MNKD )
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( NASDAQ: MNKD ) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZIMV, ARIS, SCPH on Behalf of Shareholders - Aris Water Solutions ( NYSE:ARIS ) , scPharmaceuticals ( NASDAQ:SCPH )
NEW YORK, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ZimVie Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - GTLS, SCPH, VTLE, and VRNT
NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Why Is Denali Therapeutics ( DNLI ) Up 16.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Apollo Asset Management ( NYSE:APO ) , Air Lease ( NYSE:AL )
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Air Lease Corporation AL rose sharply during Tuesday's session after the aircraft lessor said it will be acquired by a newly formed Dublin-based holding company backed by Sumitomo Corp.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMXI, HBI, VTLE, SCPH on Behalf of Shareholders - International Money ( NASDAQ:IMXI ) , Hanesbrands ( NYSE:HBI )
NEW YORK, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: International Money Express, Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. ( Nasdaq - SCPH ) , Vital Energy, Inc. ( NYSE - VTLE ) , International Money Express, Inc. ( Nasdaq - IMXI ) , HanesBrands Financial Corp. ( NYSE - HBI )
BALA CYNWYD, Pa., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy - MannKind ( NASDAQ:MNKD ) , United Therapeutics ( NASDAQ:UTHR )
DANBURY, Conn. and BOSTON, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD today announced that United Therapeutics Corporation UTHR has exercised its option-granted under the companies' 2018 license and collaboration agreement-to develop a second dry powder inhalation therapy.
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
DANBURY, Conn. and BOSTON, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) today announced that United Therapeutics Corporation ( Nasdaq: UTHR ) has exercised its option-granted under the companies' 2018 license and collaboration agreement-to develop a second dry powder ...
New Strong Sell Stocks for August 27th
CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders - scPharmaceuticals ( NASDAQ:SCPH ) , Vital Energy ( NYSE:VTLE )
NEW YORK, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Vital Energy, Inc.
SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind - scPharmaceuticals ( NASDAQ:SCPH )
MONSEY, N.Y., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc.
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal - scPharmaceuticals ( NASDAQ:SCPH ) , MannKind ( NASDAQ:MNKD )
MannKind to buy scPharmaceuticals for $5.35 per share plus CVR, valuing the deal at up to $360 million. Furoscix sales rose 96% YoY in H1 2025, with Q3 sNDA submission planned for ReadyFlow Autoinjector. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) and scPharmaceuticals Inc. ( Nasdaq: SCPH ) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases - MannKind ( NASDAQ:MNKD ) , scPharmaceuticals ( NASDAQ:SCPH )
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
• Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need • Upfront cash payment of $5.35 per share plus one non-tradable contingent ...
Amphastar ( AMPH ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 9:00 p.m. ETChief Executive Officer - Dan DischnerContinue reading ...
Pulmatrix ( PULM ) Q2 Revenue Falls 100%
Pulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.
MannKind ( MNKD ) Q2 Revenue Rises 6%
MannKind ( NASDAQ:MNKD ) , a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from this release was a 6% increase in total revenue to $76.53 million ( GAAP ) , primarily from ...
MannKind ( MNKD ) Reports Break-Even Earnings for Q2
MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement - MannKind ( NASDAQ:MNKD )
Strengthens MannKind's capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
• MannKind to receive $75 million in cash at closing
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
• Advanced pipeline: • MNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) today reported financial results for the second quarter 2025 and provided a business ...
AbCellera Biologics Inc. ( ABCL ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ABCELLERA BIOLG (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate MannKind ( MNKD ) to Report a Decline in Earnings: What to Look Out for
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amarin ( AMRN ) Soars 27.3%: Is Further Upside Left in the Stock?
Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Top 3 Health Care Stocks That May Rocket Higher This Quarter - INVO Fertility ( NASDAQ:IVF ) , MannKind ( NASDAQ:MNKD )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin ( Afrezza® ) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23 - MannKind ( NASDAQ:MNKD )
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD, a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled ...
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin ( Afrezza® ) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Session ...
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
Only known U.S. pro racing driver competing full-time with Type 1 diabetes will share an inspirational message to kick off Chevrolet Detroit Grand Prix week Only known U.S. pro racing driver competing full-time with Type 1 diabetes will share an inspirational message to kick off Chevrolet ...
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29 - MannKind ( NASDAQ:MNKD )
WESTLAKE VILLAGE, Calif., May 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes ( T1D ) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit ...
MannKind ( MNKD ) Beats Q1 Earnings and Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 33.33% and 5.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 9:00 am ET ...
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 9:00 am ET • Advanced pipeline: • Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025 • MNKD-201: Expect to continue to next phase of global development in 2H 2025
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Ligand Pharmaceuticals ( NASDAQ:LGND ) , MannKind ( NASDAQ:MNKD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Joshua Dennerlein initiated coverage on MSCI Inc.
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - MannKind ( NASDAQ:MNKD )
Five presentations affirm positive outcomes utilizing inhaled insulin An sNDA filing for Afrezza in pediatric population anticipated in 2025
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March ...
